製品番号: HY-179572

STA-013

カスタマーレビュー

Based on 1 Customer Validation

STA-013 is a EphB tyrosine kinase inhibitor. STA-013 shows promising potency against EphB1 (IC₅₀ = 0.69 µM), EphB2 (IC₅₀ = 1.73 µM), and EphB4 (IC₅₀ = 1.02 µM) tyrosine kinases. STA-013 results a inhibition of the EphB phosphorylated signal, coupled with increased p-AKT/AKT signaling, to suggest insulin signaling activation. STA-013 inhibits EphB tyrosine kinase by enhancing insulin receptor beta (IRβ) signaling, and decreasing TGF-β levels in the heart. STA-013 can be used for the study of type 2 diabetes and cardiac complications (diabetic cardiomyopathy).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.18%
分子式: C₂₄H₁₇N₃O₂S
分子量:411.48

保管条件:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

STA-013 構造式

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- Parmacokinetics
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

ErbB1

0.69 μM (IC₅₀)

ErbB2

1.73 μM (IC₅₀)

ErbB4

1.02 μM (IC₅₀)

EGFR アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

体外実験

STA-013 (5 µM) inhibits EphB1 (54%), EphB2 (42%), EphB4 (52%), SGK1 (47%), and PKBb (43%) without affecting the rest of 140 kinases via kinome profiling assay^[1].
STA-013 (0.032-20 µM, 96 h) significantly inhibits lipid accumulation in a dose-dependent manner in the embryonic mouse 3T3-L1 cells^[1].
STA-013 (1 µM, 30 min) results a significant reduction in basal respiration, proton leak, ATP production, and non-mitochondrial oxygen consumption, increases maximal respiration and spare respiratory capacity, exhibits a significant increase in glycolysis and glycolytic capacity and reduces palmitate oxidation in 3T3-L1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	C_max	T_max	AUC	F	C₀	T_1/2 (Metabolic)	AUC_inf	CL	V_{ss_obs}
Mice^[1]	25 mg/kg	i.p.	1126 ng/mL	0.35 h	0.158 mL/min	0.75	/	/	/	/	/
Mice^[1]	25 mg/kg	i.v.	/	/	/	/	1404 ng/mL	16.10 h	0.212 mL/min	10.50 L/h/kg	88.8 L/kg

体内実験

STA-013 (12.5, 25 and 50 mg/kg, i.p., daily for 6 weeks) promotes weight loss, improves glucose clearance and insulin sensitivity, and enhances insulin signaling in isolated brown adipose tissue and liver in high-fat diet-induced C57BL/6J mice. In these obese mice ^[1].
STA-013 (12.5, 25 and50 mg/kg, i.p., daily for 6 weeks) induces weight loss not through reduced food intake or elevated metabolic rates in DIO mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HFD (for 10 weeks) induced male C57BL/6J mice (16-20 weeks old)^[1]
Dosage:

12.5, 25 and 50 mg/kg
Administration:

i.p., daily for 6 weeks
Result:

Showed a significant reduction in whole-body weight, improved glucose clearance in the IP glucose tolerance test (GTT), and insulin sensitivity in the IP insulin tolerance test (ITT).
Showed a significant reduction in the fat mass associated with preserving the lean muscle mass in HFD-obese mice.
Induced intrascapular brown adipose tissue (BAT)-specific thermogenesis in HFD obese mice.
Showed significant reduction in whole-body weight associated with reduction in the fat mass (%) as well as increase in the lean mass (%), improved glucose clearance, and restored insulin sensitivity in HFD obese mice.
Inhibited phosphorylation of ephb tyrosine kinase forward signaling in both the liver and BAT at 25 mg/kg.
Increased the p-AKT/AKT signaling, which suggests the activation of insulin signaling in BAT and liver in HFD obese mice.
Increased insr-β protein levels compared to vehicle in BAT and liver lysates.

Animal Model:

HFD (for 10 weeks) induced male C57BL/6J DIO mice (16-20 weeks old)^[1]
Dosage:

12.5, 25 and 50 mg/kg
Administration:

i.p., daily for 6 weeks
Result:

Significantly increased oxygen (VO 2 and carbon dioxide (VCO 2) consumption ) production in the light cycle.
Decreased profile in the respiratory exchange rates (RER) during the dark cycle.
Decrease in the total energy expenditure (EE) for STA- 013 treated HFD mice.
Induced weight loss occurred without a change in food intake, suggesting it was due to an elevated metabolic rate.

化学情報

性状 Solid
分子量 411.48
分子式 C₂₄H₁₇N₃O₂S
Color White to light yellow
SMILES

O=C(NCC1=CC=CC2=C1C=CN2C(C3=CC=CC=C3)=O)C4=CC5=CC=CN=C5S4
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 25 mg/mL (60.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4303 mL

12.1513 mL

24.3025 mL

5 mM

0.4861 mL

2.4303 mL

4.8605 mL

10 mM

0.2430 mL

1.2151 mL

2.4303 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Tareq S,et al. Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice. Pharmacol Res. 2025 Sep;219:107900. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4303 mL	12.1513 mL	24.3025 mL	60.7563 mL
	5 mM	0.4861 mL	2.4303 mL	4.8605 mL	12.1513 mL
	10 mM	0.2430 mL	1.2151 mL	2.4303 mL	6.0756 mL
	15 mM	0.1620 mL	0.8101 mL	1.6202 mL	4.0504 mL
	20 mM	0.1215 mL	0.6076 mL	1.2151 mL	3.0378 mL
	25 mM	0.0972 mL	0.4861 mL	0.9721 mL	2.4303 mL
	30 mM	0.0810 mL	0.4050 mL	0.8101 mL	2.0252 mL
	40 mM	0.0608 mL	0.3038 mL	0.6076 mL	1.5189 mL
	50 mM	0.0486 mL	0.2430 mL	0.4861 mL	1.2151 mL
	60 mM	0.0405 mL	0.2025 mL	0.4050 mL	1.0126 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

STA-013

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

EGFR アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

STA-013 関連分類

HY-179572 関連分類